Correspondingly, CTLA-4 inhibitors (e.g., ipilimumab and tremelimumab)—alone or in combination—are more frequently associated with GI irAEs, such as enterocolitis or hepatitis, as opposed to PD-1/PD-L1 blockade alone [6,13,14]. The gene discussed is CTLA4; the disease is enterocolitis.